Q1 EPS Forecast for Sarepta Therapeutics Boosted by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $1.98 per share for the quarter, up from their previous forecast of $1.80. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.16 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2026 earnings at $3.66 EPS and Q3 2026 earnings at $3.63 EPS.

Several other research analysts also recently weighed in on the company. UBS Group upped their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. HC Wainwright lowered their target price on Sarepta Therapeutics from $80.00 to $75.00 and set a “sell” rating for the company in a research report on Tuesday. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 target price for the company. Finally, Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $175.55.

Sarepta Therapeutics Trading Down 1.5 %

SRPT stock opened at $126.01 on Monday. Sarepta Therapeutics has a 1-year low of $83.97 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company has a market capitalization of $12.04 billion, a price-to-earnings ratio of 100.81 and a beta of 0.77. The business has a 50 day simple moving average of $122.56 and a two-hundred day simple moving average of $131.44.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its holdings in Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after acquiring an additional 665,087 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after acquiring an additional 44,306 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Sarepta Therapeutics by 9.2% in the third quarter. Jacobs Levy Equity Management Inc. now owns 753,845 shares of the biotechnology company’s stock worth $94,148,000 after acquiring an additional 63,437 shares in the last quarter. Finally, Thrivent Financial for Lutherans boosted its holdings in Sarepta Therapeutics by 6.3% in the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after acquiring an additional 37,940 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.